Trial reportSleep medicine2011
Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers.
Trial report in Sleep medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- New Antipsychotic Medications in the Last Decade.Current psychiatry reports · 2021Pooled it
- Novel applications of sleep pharmacology as delirium therapeutics.Sleep medicine reviews · 2025Review
- Sedation and sleep safety of pimavanserin for Parkinsons's disease psychosis: Review and exploratory analysis of clinical study data.Clinical parkinsonism & related disorders · 2025Review
- Pimavanserin 34 mg at Bedtime for the Treatment of Insomnia in 6 Veterans With Posttraumatic Stress Disorder.The Journal of clinical psychiatry · 2023Article
- An examination of sleep spindle metrics in the Sleep Heart Health Study: superiority of automated spindle detection over total sigma power in assessing age-related spindle decline.BMC neurology · 2023Article
- Clinical Evaluation of Sleep Disorders in Parkinson's Disease.Brain sciences · 2023Review
- "Selective" serotonin 5-HTBiochemical pharmacology · 2022Review
- Pimavanserin, a 5HTJournal of neurochemistry · 2021Article
- Novel pharmacological treatments for generalized anxiety disorder: Pediatric considerations.Depression and anxiety · 2020Review
- The 5-HTThe Journal of pharmacology and experimental therapeutics · 2019Article
- Pimavanserin use in a movement disorders clinic: a single-center experience.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018Article
- Novel Bivalent 5-HTACS chemical neuroscience · 2018Article
- Development of a UPLC-MS/MS method for determination of pimavanserin tartrate in rat plasma: Application to a pharmacokinetic study.Journal of pharmaceutical analysis · 2017Article
- Treatment of Sleep Dysfunction in Parkinson's Disease.Current treatment options in neurology · 2017Review
- Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission.Psychopharmacology · 2015Article
- On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.Neurochemical research · 2014Review
- Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction.Neuropharmacology · 2014Review
- Role of 5-HT2A receptor antagonists in the treatment of insomnia.Nature and science of sleep · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
Abstract
objectiveDetermine the effects of pimavanserin tartrate [ACP-103; N-(4-flurophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide], a selective serotonin 5-HT(2A) receptor inverse agonist, on slow wave sleep (SWS), other sleep parameters, and attention/vigilance.
methodsForty-five healthy adults were randomized to pimavanserin (1, 2.5, 5, or 20 mg) or placebo in a double-blind fashion (n=9/group). Pimavanserin or placebo was administered once daily in the morning for 13 consecutive days. The effects of pimavanserin were measured after the first dose and again after 13 days. Sleep parameters were measured by polysomnography. Effects on attention/vigilance were measured by a continuous performance task.
resultsCompared to placebo, pimavanserin significantly increased SWS following single and multiple dose administration. Pimavanserin also decreased number of awakenings. PSG variables not affected by pimavanserin included sleep period time, total sleep time, sleep onset latency, number of stage shifts, total time awake, early morning wake, and microarousal index. Changes in sleep architecture parameters, sleep profile parameters, and spectral power density parameters were consistent with a selective increase in SWS. Pimavanserin did not adversely affect performance on the continuous performance test measured in the evening before or morning after polysomnography.
conclusionsThese data suggest that pimavanserin selectively increases slow wave sleep and decreases awakenings, an effect that does not diminish with repeated administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.